GlassScriptPhysician profile
Paula A Spinks
NPI 1871875476
$2,177.68
in general payments reported to CMS, 2019-2025
15 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $112 · 2023: $736 · 2024: $923 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $352.02 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $327.65 | 2024-2025 | Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $255.00 | 2023-2024 | Entyvio, Eohilia |
| Bayer Healthcare Pharmaceuticals INC. | $155.68 | 2023 | |
| Janssen Scientific Affairs, LLC | $130.43 | 2022-2024 | Tremfya |
| Aimmune Therapeutics, INC. | $124.98 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $124.74 | 2024 | |
| Phathom Pharmaceuticals, INC. | $123.50 | 2024 | Voquezna |
| Janssen Biotech, INC. | $121.35 | 2024 | Stelara, Tremfya |
| Amgen INC. | $120.96 | 2023 | Avsola |
| Novo Nordisk INC | $118.50 | 2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $87.83 | 2025 | |
| Neurelis, INC. | $81.83 | 2023 | Valtoco |
| Mauna Kea Technologies, INC. | $31.70 | 2024 | |
| Merck Sharp & Dohme LLC | $21.51 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Spinks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.